Trial Profile
Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms ASCERTAIN
- Sponsors Novartis
- 21 Apr 2012 Planned number of patients changed from 395 to 490 as reported by European Clinical Trials Database record.
- 21 Jun 2011 Primary endpoint 'Glomerular-filtration-rate' has not been met, as published in Transplantation.
- 21 Jun 2011 Results published in Transplantation.